I
n hypertension, cardiac autonomic impairment is an important contributor to the pathophysiological phenotype of the disease. Much evidence supports the observation that the activity of the sympathetic nervous system increases dramatically both in hypertensive patients [1] [2] [3] [4] and in the spontaneously hypertensive rat (SHR). 5, 6 The mechanism causing enhanced neurohumoral activation is unknown, but may be directly related to oxidative stress caused by hypertension disrupting nitric oxide (NO)-cGMP modulation of norepinephrine (NE) release in central autonomic nuclei 7 and peripheral varicosities. 8 Neuronal production of NO affects cardiac excitability through its action as a neuromodulator of postganglionic sympathovagal transmission. 8 -10 Both endogenous and exogenous NO inhibits evoked NE release during cardiac sympathetic nerve stimulation in the rat in vitro. 11 Functionally, NO or the membrane-permeable cGMP analogue 8-bromo-cGMP decreases the heart rate response to sympathetic nerve stimulation in vitro, whereas NO synthase (NOS) inhibitors causes the opposite effect. 12 In addition, oxidative stress caused by intermittent hypoxia decreases cardiac sympathetic neuronal NOS (nNOS) expression, which is associated with an enhanced heart rate response to sympathetic activation. 13 Moreover, soluble guanylate cyclase (sGC), the key precursor of cGMP-dependent effects of NO, is downregulated in the aorta 14 and the atria 15 of the SHR. Tetrahydrobiopterin (BH 4 ) and total biopterin levels are not different between SHR and Wistar-Kyoto (WKY) rat atria where sympathetic nerves innervate the heart, suggesting that BH 4 is not uncoupled from NOS. 15 Therefore strategies aimed at increasing bioavailability of NO could be advantageous in rescuing this impaired neural phenotype.
Gene transfer with adenoviral vectors is highly effective in modifying gene expression and has been used with good effect to understand whether changes in protein expression or enzyme activity play a key role in physiological function. 16 -18 Because adenoviruses transduce a broad range of cells, the gene of interest can be placed into cells that may not constitutively express them, thereby complicating the interpretation of the data. To minimize this limitation, we have recently developed a novel adenoviral vector constructed with a noradrenergic neuron-specific promoter (PRS ϫ8) to drive nNOS or enhanced green fluorescence protein (eGFP) expression, and showed that nNOS targeted to only cardiac sympathetic neurons can inhibit noradrenergic neurotransmission and increase nNOS activity in normotensive rats. 19 We therefore examined the hypothesis that a significant component of cardiac sympathetic hyper-responsiveness in hypertension occurs at the end organ level because of impaired NO-cyclic nucleotide signaling. From this we further hypothesized that gene transfer with a noradrenergic cell specific promoter coupled to nNOS could increase the bioactivity of nNOS and the production of cGMP that results in restoration of sympathetic transmission in the SHR to similar responses seen in the WKY rat.
Materials and Methods
An extended methods and results section can be found in the online data supplement available at http://hyper.ahajournals.org.
Animals
Age-matched (16 to 20 weeks old) male SHR (nϭ28) and WKY rats (nϭ28), young Sprague-Dawley (SD) rats (8 to 13 days old; nϭ6) were purchased from Harlan (Bicester, UK) and housed under standard laboratory conditions. The investigation conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) and the Animals (Scientific Procedures) Act 1986 (UK) and were performed under British Home Office license requirements (PPL 30/2130).
Gene Transfer Procedure
Replication-deficient adenoviral vectors encoding recombinant eGFP or nNOS under control of the noradrenergic neuron-specific promoter (PRS ϫ8) were generated as described previously. 19 Targeted percutaneous gene transfer to the right atrium was performed under isoflurane (Isocare, Animalcare Ltd) anesthesia (4% for induction and 2% to 3% for maintenance, in 100% O 2 ), using a technique similar to that described previously for the guinea pig. 9 SHRs or WKY rats received an injection of 5ϫ10 10 particles of Ad.PRS-nNOS or Ad.PRS-eGFP in 300 L of phosphate-buffered saline. Experiments were performed Ϸ5 days after injection.
[ 3 H]Norepinephrine Release Experiments on the Isolated Right Atrium
An isolated right atrium preparation was generated by the method described previously 20 with some modification. Details and experimental protocols may be found in the online data supplement.
Immunohistochemistry
Cardiac sympathetic neuron isolation and transduction was prepared by the method described previously. 19 Detailed methods for immunohistochemistry may be found in the online data supplement.
Measurement of Tissue cGMP Levels and NOS Activity
Details may be found in the online data supplement.
Solutions and Drugs
Rat Tyrode solution contained (in mmol/L): NaCl 120, KCl 4.7, MgSO 4 1.2, KH 2 PO 4 1.2, NaHCO 3 25, CaCl 2 2, and glucose 11. The solution was constantly aerated with carbogen to maintain pH at 7.4. All solutions were prepared fresh on the day of use using deionized water obtained from an Elga water purification system. Experiments using SNP were performed in a darkened room because of the light sensitivity of this drug.
Statistical Analysis
The results are given as the meansϮSEM. Analysis was performed using the paired or unpaired Student t test as appropriate. For all experiments, statistical significance was accepted at PϽ0.05.
Results

Norepinephrine Release Was Increased in the SHR
Field stimulation-evoked release of [ 3 H] NE from right atria was significantly enhanced at 5-Hz in the SHR (S1: ϩ2.22Ϯ0.13%, S2: ϩ2.19Ϯ0.14%, nϭ5) compared with the WKY rats (S1: ϩ1.68Ϯ0.04%, S2: ϩ1.55Ϯ0.04, nϭ6, PϽ0.01, unpaired t test; Figure 1 ). S1 and S2 represent the first and second field stimulation, respectively, where there 3 H] NE release was significantly increased at both stimulation in the SHR (nϭ5) compared with the WKY (nϭ6, **PϽ0.01, unpaired t test). Percentage changes in NE release was expressed as a ratio of increase in NE radioactivity after electrical stimulation over the total radioactivity. was no difference between S1 and S2 in both strains indicating no significant time dependent changes.
Effects of SNP and ODQ on Release of Norepinephrine in Field Stimulation
To determine whether the sympathetic activated NO-cGMP pathway was impaired in the SHR, the exogenous NO donor SNP and the sGC inhibitor ODQ were applied to preparations. SNP (20 mol/L) significantly decreased the release of 
Sympathetic Neuron Specific Gene Transfer Mediated by Ad.PRS-nNOS
Majority of cultured sympathetic neurons did not have detectable amounts of endogenous nNOS. However, after 5 days after transduction with Ad.PRS-nNOS, nNOS was clearly detectable by nNOS antibody in 90% of sympathetic neurons ( Figure 4A ). nNOS expression in Ad.PRS-nNOS transduced cells colocalized with anti-TH stain ( Figure 4B ; scale bar, 50 m).
nNOS Activity After Ad.PRS-nNOS
We observed there was no difference in nNOS activity between SHR (nϭ9) and WKY (nϭ9) atria. After gene transfer with Ad.PRS-nNOS, nNOS activity was significantly enhanced in both strains compared with Ad.PRSeGFP-treated atria (eg, SHR, increased from 14.6Ϯ2.3 to 20.5Ϯ3.1 fmol/mg/min, PϽ0.05; WKY, increased from 12.9Ϯ0.4 to 16.1Ϯ1.2 fmol/mg/min, PϽ0.05, nϭ6 in each group, Figure 5 ). 
Li et al nNOS Reduces Norepinephrine Release in the SHR
Production of cGMP in Atria After Ad.PRS-nNOS
Effects of Gene Transfer With Ad.PRS-nNOS on Release of Norepinephrine
Previously, we showed that the Ad.PRS-nNOS gene transfer significantly reduced norephinephrine release evoked by field stimulation of isolated right atria in the normotensive SD rat. 19 In the present study, we observed similar results in the WKY rats ( Figure 7A 
Discussion
In the present study, we report 3 novel findings. First, a significant component of the sympathetic hyperresponsiveness in the SHR occurs postganglionically at the end organ level with enhanced evoked norepinephrine release. Secondly, this response was associated with impaired sGC-cGMP signaling in the SHR compared with the WKY rat. Thirdly, targeted gene transfer of nNOS with a noradrenergic cell specific promoter increased the bioactivity of nNOS and cGMP levels in cardiac sympathetic nerves. This resulted in decreased NE release in the SHR to levels seen in the normotensive control.
Peripheral Sympathetic Activity in the SHR
Autonomic imbalance in the central and peripheral nervous system has been implicated in the etiology of hypertension, and is also seen after myocardial infarction and heart failure. [21] [22] [23] [24] Impaired cardiac parasympathetic regulation and enhanced sympathetic activity characterize cardiac disease states, and are regarded as an independent predictor of mortality. 25, 26 Bradycardia and acetylcholine release in response to vagal nerve stimulation is reduced in the SHR at the level of the cardiac postganglionic neurons. 27 Here we observed that the norepinephrine release from right atria in response to field stimulation in the SHR was significantly higher compared with the WKY rat. This gives direct evidence that the sympathetic nervous system is hyper-reactive in the SHR at the level of heart, and is in general agreement with whole animal studies that report a global sympathetic phenotype in this model of hypertension. 28, 29 
NO-cGMP Signaling in the SHR
Defective NOS signaling via eNOS has been widely implicated in the vascular aspect of hypertension, although cumu- Figure 6 . Tissue levels of cGMP in SHR were significantly lower than that measured in WKY atria before or after genetransferred Ad.PRS-eGFP ( †PϽ0.05, unpaired t test). However, tissue cGMP were significantly increased after Ad.PRS-nNOS transfection in SHR (*PϽ0.05, unpaired t test; nϭ6 in each group). lative evidence now suggests that neuronally synthesized NO may also play a role in the pathophysiology of hypertension. 30 The signaling pathway responsible for nNOSderived NO inhibiting sympathetic neurotransmission is not completely understood. However, it could involve NO modifying cell physiology through activation of sGC and subsequent induction of cGMP production, which in turn activates cGMP-dependent protein kinase and phosphodiesterases that decrease cAMP-dependent phosphorylation of neuronal Ca 2ϩ channels resulting in decreased exocytosis of neurotransmitter. 31 Emerging data indicates that sGC, the main target protein for NO, is markedly desensitized/downregulated in hypertension. 14, [32] [33] [34] [35] In particular, downregulation of the ␣ 1 subunit of sGC in the atria and aorta of the SHR compared with WKY rat has recently been reported. 15 We observed that guanylate cyclase inhibition increased NE release in the WKY but was without effect in the SHR, suggesting functional uncoupling of NO to its second messenger. Consistent with this idea we confirmed that tissue levels of cGMP were significantly lower in the SHR compared with the WKY. Translationally, decreased sGC expression and cGMP production has been proposed to account for impaired vasodilatation in the AfroCaribbean population 36 (susceptible to hypertension), fetal programming of hypertension, 37 and in pulmonary hypertension. 38 Similarly, downregulation of the sGC-dependent pathway 34, 35 has been demonstrated in aged and spontaneously hypertensive rats where superoxide production has been reported to trigger desensitization of vascular sGC in hypertension. 34 Because nNOS activity and tetrahydrobiopterin levels in the SHR are not different compared with the WKY, this suggests uncoupling of nNOS from its main cofactor is unlikely to be the mechanism of peripheral sympathetic dysfunction in the SHR, and that the defect resides at the level of sGC-cGMP linkage.
Effect of Noradrenergic Neuron-Specific Overexpression of nNOS on Sympathetic Function in the SHR
Administration of the NO donor SNP did not decrease NE release in the SHR. It is possible that acute pharmacological administration of NO donors at a relatively low concentration (20 mol/L) may not fully mimic the action of NO generated intracellularly by the nNOS transgene, given its labile and highly reactive properties. In particular, a relatively high local concentration of NO may be required to increase the bioavailability of NO under conditions of increased oxidative stress that have been demonstrated previously in hypertension. 39, 40 In addition, a much longer period of incubation may be need to achieve the effect than that can be provided in a stable in vitro experimental environment. However, overexpression of Ad.PRS-nNOS in the SHR significantly decreased the [ 3 H] NE release compared with Ad.PRS-eGFP, and the sGC inhibitor ODQ significantly increased the NE release from Ad.PRS-nNOS-transduced SHR atria. The noradrenergic promoter is highly specific with no detectable leakage of gene expression into other cell types. 19 Transduction with Ad.PRSnNOS increased nNOS activity in the atrial extracts and enhanced atrial cGMP levels compared with Ad.PRS-eGFP.
Importantly, gene transfer of adenovirus nNOS can also increase the expression of the defective ␣ 1 subunit of sGC in the SHR, 27 which appears to be the key step for the functional changes. The mechanism underpinning this observation is not known, but when results are taken together they show that nNOS gene transfer provided a more potent NO signal than the NO donor.
Perspectives
Enhanced presynaptic postganglionic release of NE is not the only site of defective autonomic signaling in hypertension. nNOS gene transfer into the paraventricular nucleus can also decrease sympathetic outflow in the rat. 41 In addition, our group 15 recently found that the atria of the SHR were hyper-responsive to ␤-adrenergic stimulation which was associated with elevated cAMP levels. This was accompanied by an increased basal and norepinephrine-stimulated L-type calcium current (I CaL ) in single sinoatrial node cells. Gene transfer of nNOS decreased cAMP and the norepinephrine stimulated I CaL in the SHR. Combined with the present study, these results support the role of nNOS-sGC-cGMP in modulating peripheral noradrenergic activity at both presynaptic and postsynaptic levels, and that gene transfer of nNOS into either neurons or into pacemaking tissue can rescue the peripheral sympathetic hyperactivity seen in the SHR. Given the autocrine and paracrine action of NO in the heart, targeting both myocytes and sympathetic neurons with nNOS could be beneficial where this gaseous messenger may behave like a "smart beta blocker" that decreases overall adrenergic drive at these 2 sites. Whether this approach is viable to treat hyper-responsive sympathetic and beta adrenergic phenotypes remains to be established.
Methods
[ 3 H]Norepinephrine release experiments on the isolated right atrium
Experiment set up
SHRs and WKY rats were used. An isolated right atrium preparation was generated by the method described previously 1 with some modification. Briefly, animals were euthanatized with intraperitoneal injection of pentobarbitone. The right atria were removed and transferred to preheated organ bath containing Tyrode's solution. After a 45 minute equilibration, the atrium was incubated with 5 µCi l- [7, 
Experimental protocols
Experiments were carried out by using three groups of atria to define neurotransmitter release (Fig. S1 ). Control cycles (30 min) were followed by using the NO donor sodium nitroprusside was stimulated at 5Hz for 1 minute at the beginning of the 16 th (S1) and 76 th (S2) minutes (in group 2, stimulated at the 46 th (S2) minutes). At the end of the experiment, the atrium was immersed overnight in 3 ml Tyrode's solution containing 4 U/ml papain (Sigma) and the radioactivity contained in the extract was determined.
the supernatant was extracted with water-saturated ether 3 times and then dried using a SpeedVac concentrator (Savant). The dried samples were resuspended and a 125 I-cGMP kit (Amersham UK) was used to measure the amount of cGMP level, with the bound form separated from the free form using magnetic separation. The pellet was treated with 500 µL NaOH (1N) and used for protein quantification.
Measurement NOS activity
NOS activity in atria was quantified by measuring the conversion of 
